SAN DIEGO, June 24, 2018 /PRNewswire-USNewswire/
-- Renova™ Therapeutics, a biotechnology company developing
gene and peptide-based treatments for cardiovascular and metabolic
diseases, announced today that an abstract of a study in a
preclinical model of type 1 diabetes was accepted as a
late-breaking poster presentation at the upcoming American Diabetes
Association 78th Scientific Sessions being held in
Orlando from June 22-26, 2018.
In a blinded study, urocortin 2 (UCn2) gene-treated Akita mice
showed normalization of fasting blood glucose, HbA1c and glucose
tolerance, along with normalization of body weight and a reduction
in water intake, when compared to a control group (AAV8.null or
saline treated) of Akita diabetic mice. Urocortin 2 gene-treated
mice also exhibited improved insulin sensitivity, increased
skeletal muscle glucose uptake, reduction in nephropathy and
retinopathy, and a marked increase in survival. Treated mice also
showed increased cardiac function (echocardiography). The study was
conducted at the VA San Diego and
UC San Diego.
The poster is scheduled to be presented on Monday, June 25, 2018 from 12:00 pm – 1:00 pm
ET. Poster presentation number 242-LB: Category 20-D
Insulin Action–Signal Transduction, Insulin, and Other
Hormones.
Renova Therapeutics holds worldwide, exclusive licenses to
patents covering UCn2 products, their uses and methods of
delivery.
About Renova Therapeutics
Renova Therapeutics is developing definitive, one-time gene
therapies and peptide administration treatments to restore the
health of people suffering from chronic diseases. The first
indications the company is pursuing are gene therapy treatments for
heart failure and type 2 diabetes, two of the most common and
devastating chronic diseases in the world. The company's lead
product candidate, RT-100, is a treatment that delivers a
therapeutic gene directly to the heart during a routine outpatient
procedure and has the potential to increase heart function in
millions of patients with heart failure. The company's product
pipeline also includes a groundbreaking gene therapy in preclinical
stage for sufferers of type 2 diabetes, as well as a peptide
infusion therapy for the treatment of acute decompensated heart
failure. Renova Therapeutics was founded in 2009 and is led by an
experienced management team in biopharmaceuticals and gene therapy.
For additional information about the company, please visit
www.renovatherapeutics.com.
View original content with
multimedia:http://www.prnewswire.com/news-releases/renova-therapeutics-announces-an-abstract-to-be-presented-at-the-late-breaking-scientific-session-of-2018-american-diabetes-association-meeting-urocortin-2-gene-transfer-effectively-treats-type-1-diabetes-300670455.html
SOURCE Renova Therapeutics